SINGAPORE, May 5 (Reuters) – Impact Therapeutics, a Chinese cancer-drug developer, aims to raise up to $117 million in a Hong Kong initial public offering, according to a term sheet seen by Reuters on Tuesday.
• Impact is offering 41.98 million shares at HK$19.75 to HK$21.75 ($2.52 to $2.78) each.
• The deal could rise to $134 million if underwriters use an over-allotment option.
• Six cornerstone investors, including Tencent, will buy about $35.7 million of the stock.
• Impact expects to price the IPO on May 11 and list on May 13.
($1 = 7.8329 Hong Kong dollars)
(Reporting by Yantoultra Ngui; Editing by Muralikumar Anantharaman)
